Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood cells may hold key to lung cancer treatment success

NCT ID NCT07363811

Recruiting now Knowledge-focused Sponsor: Necmettin Erbakan University Source: ClinicalTrials.gov ↗

First seen Jan 26, 2026 · Last updated May 12, 2026 · Updated 14 times

Summary

This study is for people with advanced non-small cell lung cancer who are starting the immunotherapy drug nivolumab. Researchers want to see if the level of certain immune cells, called large granular lymphocytes, in the blood can help predict how well the treatment works. About 50 participants will have blood tests at the start and after three months of treatment. The goal is to find a simple way to tell early on if the treatment is helping.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Necmettin Erbakan University Faculty of Medicine, Department of Medical Oncology

    RECRUITING

    Konya, Meram, 42090, Turkey (Türkiye)

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER